Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has announced Monday that it has got a Complete Response Letter (CRL) from FDA. The company disclosed that in CRL FDA declared that they need resubmission of NDA as the current application is not as per their priorities. Adamis